DNA vaccines for biodefense

References

• Hartikka J, Bozoukova V, Ferrari M et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine19(15–16), 1911–1923 (2001).
   PubMed Web of Science ®Google Scholar
• Fuller DH, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods40(1), 86–97 (2006).
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Evans CF, Hannaman D. Electroporation-based DNA immunisation: translation to the clinic. Expert Opin Biol. Ther.7(11), 1647–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Milne JC, Blanke SR, Hanna PC, Collier RJ. Protective antigen-binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol.15(4), 661–666 (1995).
   PubMed Web of Science ®Google Scholar
• Duesbery NS, Webb CP, Leppla SH et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science280(5364), 734–737 (1998).
   PubMed Web of Science ®Google Scholar
• Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl Acad. Sci. USA79(10), 3162–3166 (1982).
   PubMed Web of Science ®Google Scholar
• Ivins BE, Welkos SL. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect. Immun.54(2), 537–542 (1986).
   PubMed Web of Science ®Google Scholar
• Welkos S, Little S, Friedlander A et al. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology147(Pt 6), 1677–1685 (2001).
   PubMedGoogle Scholar
• Welkos SL. Plasmid-associated virulence factors of non-toxigenic (pX01-) Bacillus anthracis. Microb. Pathog.10(3), 183–198 (1991).
   PubMedGoogle Scholar
• Perkins SD, Flick-Smith HC, Garmory HS, Essex-Lopresti AE, Stevenson FK, Phillpotts RJ. Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax. Genet. Vaccines Ther.3(1), 3 (2005).
   PubMedGoogle Scholar
• Pitt ML, Little SF, Ivins BE et al.In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine19(32), 4768–4773 (2001).
   PubMed Web of Science ®Google Scholar
• Welkos SL, Vietri NJ, Gibbs PH. Non-toxigenic derivatives of the Ames strain of Bacillus anthracis are fully virulent for mice: role of plasmid pX02 and chromosome in strain-dependent virulence. Microb. Pathog.14(5), 381–388 (1993).
   PubMedGoogle Scholar
• Welkos SL, Keener TJ, Gibbs PH. Differences in susceptibility of inbred mice to Bacillus anthracis. Infect. Immun.51(3), 795–800 (1986).
   PubMed Web of Science ®Google Scholar
• Welkos SL, Friedlander AM. Pathogenesis and genetic control of resistance to the Sterne strain of Bacillus anthracis. Microb. Pathog.4(1), 53–69 (1988).
   PubMed Web of Science ®Google Scholar
• Welkos SL, Friedlander AM. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog.5(2), 127–139 (1988).
   PubMed Web of Science ®Google Scholar
• Flick-Smith HC, Waters EL, Walker NJ et al. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain. Microb. Pathog.38(1), 33–40 (2005).
   PubMedGoogle Scholar
• Gu ML, Leppla SH, Klinman DM. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine17(4), 340–344 (1999).
   PubMed Web of Science ®Google Scholar
• Tucker SN, Lin K, Stevens S, Scollay R, Bennett MJ, Olson DC. Systemic and mucosal antibody responses following retroductal gene transfer to the salivary gland. Mol. Ther.8(3), 392–399 (2003).
   PubMedGoogle Scholar
• Riemenschneider J, Garrison A, Geisbert J et al. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine21(25–26), 4071–4080 (2003).
   PubMed Web of Science ®Google Scholar
• Luxembourg A, Hannaman D, Nolan E et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine26(40), 5216–5222 (2008).
   PubMed Web of Science ®Google Scholar
• Hahn UK, Alex M, Czerny CP, Bohm R, Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int. J. Med. Microbiol.294(1), 35–44 (2004).
   PubMed Web of Science ®Google Scholar
• Hahn UK, Aichler M, Boehm R, Beyer W. Comparison of the immunological memory after DNA vaccination and protein vaccination against anthrax in sheep. Vaccine24(21), 4595–4597 (2006).
   PubMed Web of Science ®Google Scholar
• Ribeiro S, Rijpkema SG, Durrani Z, Florence AT. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int. J. Pharm.331(2), 228–232 (2007).
   PubMed Web of Science ®Google Scholar
• Midha S, Bhatnagar R. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses. Eur. J. Immunol.39(1), 159–177 (2009).
   PubMed Web of Science ®Google Scholar
• Price BM, Liner AL, Park S, Leppla SH, Mateczun A, Galloway DR. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun.69(7), 4509–4515 (2001).
   PubMed Web of Science ®Google Scholar
• Hermanson G, Whitlow V, Parker S et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc. Natl Acad. Sci. USA101(37), 13601–13606 (2004).
   PubMed Web of Science ®Google Scholar
• Vilalta A, Mahajan RK, Hartikka J et al. II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. Hum. Gene Ther.16(10), 1151–1156 (2005).
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM et al. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum. Vaccin.5(8), 536–544 (2009).
   PubMed Web of Science ®Google Scholar
• Hahn UK, Boehm R, Beyer W. DNA vaccination against anthrax in mice – combination of anti-spore and anti-toxin components. Vaccine24(21), 4569–4571 (2006).
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Hanna PC, Imperiale MJ. Adenovirus-based prime–boost immunization for rapid vaccination against anthrax. Mol. Ther.15(1), 203–210 (2007).
   PubMed Web of Science ®Google Scholar
• Leroy EM, Epelboin A, Mondonge V et al. Human ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Towner JS, Amman BR, Sealy TK et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog.5(7), e1000536 (2009).
   PubMed Web of Science ®Google Scholar
• Alibek K, Handelman S. Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World Told. Dell Publishing, NY, USA (1999).
   Google Scholar
• Towner JS, Sealy TK, Khristova ML et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog.4(11), e1000212 (2008).
   PubMed Web of Science ®Google Scholar
• Feldmann H, Geisbert T, Jahrling P et al.Virus Taxonomy: VIIIth Report of the International Committee on Taxonomy of Viruses. Fauquet C, Mayo M, Maniloff J, Desselberger U, Ball L (Eds). Elsevier/Academic Press, CA, USA (2005).
   Google Scholar
• Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine25(11), 1923–1934 (2007).
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Volchkova VA, Muhlberger E et al. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science291(5510), 1965–1969 (2001).
   PubMed Web of Science ®Google Scholar
• Volchkov VE, Feldmann H, Volchkova VA, Klenk HD. Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl Acad. Sci. USA95(10), 5762–5767 (1998).
   PubMed Web of Science ®Google Scholar
• Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis.179(Suppl. 1), S248–S258 (1999).
   PubMed Web of Science ®Google Scholar
• Warfield KL, Bradfute SB, Wells J et al. Development and characterization of a mouse model for marburg hemorrhagic fever. J. Virol.83(13), 6404–6415 (2009).
   PubMed Web of Science ®Google Scholar
• Vanderzanden L, Bray M, Fuller D et al. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. Virology246(1), 134–144 (1998).
   PubMed Web of Science ®Google Scholar
• Xu L, Sanchez A, Yang Z et al. Immunization for Ebola virus infection. Nat. Med.4(1), 37–42 (1998).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature408(6812), 605–609 (2000).
   PubMed Web of Science ®Google Scholar
• Martin JE, Sullivan NJ, Enama ME et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol.13(11), 1267–1277 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan NJ, Geisbert TW, Geisbert JB et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature424(6949), 681–684 (2003).
   PubMed Web of Science ®Google Scholar
• Richardson JS, Yao MK, Tran KN et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS ONE4(4), e5308 (2009).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Geisbert JB, Leung A et al. Single injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus. J. Virol.83(14), 7296–7304 (2009).
   PubMed Web of Science ®Google Scholar
• Geisbert TW, Daddario-Dicaprio KM, Lewis MG et al. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog.4(11), e1000225 (2008).
   PubMed Web of Science ®Google Scholar
• Swenson DL, Wang D, Luo M et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccine Immunol.15(3), 460–467 (2008).
   PubMed Web of Science ®Google Scholar
• Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol.77(1), 799–803 (2003).
   PubMed Web of Science ®Google Scholar
• Hevey M, Negley D, Van der Zanden L et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine20(3–4), 586–593 (2001).
   PubMed Web of Science ®Google Scholar
• Galmiche MC, Goenaga J, Wittek R, Rindisbacher L. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology254(1), 71–80 (1999).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology266(2), 329–339 (2000).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology306(1), 181–195 (2003).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Golden JW, Ferro AM, King AD. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine25(10), 1814–1823 (2007).
   PubMed Web of Science ®Google Scholar
• Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine22(25–26), 3358–3366 (2004).
   PubMed Web of Science ®Google Scholar
• Sakhatskyy P, Wang S, Chou TH, Lu S. Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen. Virology355(2), 164–174 (2006).
   PubMed Web of Science ®Google Scholar
• Golden JW, Josleyn MD, Hooper JW. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. Vaccine26(27–28), 3507–3515 (2008).
   PubMed Web of Science ®Google Scholar
• Shinoda K, Wyatt LS, Irvine KR, Moss B. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization. Virol. J.6, 28 (2009).
   PubMedGoogle Scholar
• Su HP, Golden JW, Gittis AG, Hooper JW, Garboczi DN. Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. Virology368(2), 331–341 (2007).
   PubMed Web of Science ®Google Scholar
• Hooper JW, Thompson E, Wilhelmsen C et al. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol.78(9), 4433–4443 (2004).
   PubMed Web of Science ®Google Scholar
• Otero M, Calarota SA, Dai A, De Groot AS, Boyer JD, Weiner DB. Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine24(21), 4461–4470 (2006).
   PubMed Web of Science ®Google Scholar
• Heraud JM, Edghill-Smith Y, Ayala V et al. Subunit recombinant vaccine protects against monkeypox. J. Immunol.177(4), 2552–2564 (2006).
   PubMed Web of Science ®Google Scholar
• Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology371(1), 98–107 (2008).
   PubMed Web of Science ®Google Scholar
• Golden JW, Hooper JW. Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. Virology377(1), 19–29 (2008).
   PubMed Web of Science ®Google Scholar
• Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan equine encephalitis virus. Vaccine18(7–8), 588–596 (1999).
   PubMedGoogle Scholar
• Nagata LP, Hu WG, Masri SA et al. Efficacy of DNA vaccination against western equine encephalitis virus infection. Vaccine23(17–18), 2280–2283 (2005).
   PubMedGoogle Scholar
• Dupuy LC, Locher CP, Paidhungat M et al. Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine. Vaccine27(31), 4152–4160 (2009).
   PubMedGoogle Scholar
• Perkins SD, O’Brien LM, Phillpotts RJ. Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Vaccine24(17), 3440–3445 (2006).
   PubMed Web of Science ®Google Scholar
• Zanin MP, Webster DE, Wesselingh SL. A DNA prime, orally delivered protein boost vaccination strategy against viral encephalitis. J. Neurovirol.13(3), 284–289 (2007).
   PubMed Web of Science ®Google Scholar
• Dupuy LC, Richards M, Ellefsen B, Hannaman D, Livingston B, Schmaljohn SC. Improved potency of codon-optimized encephalitic alphavirus DNA vaccines delivered by electroporation. Presented at: 7th Annual ASM Biodefense and Emerging Diseases Research Meeting. Baltimore, MD, USA, 22–25 February 2009.
   Google Scholar
• Williamson ED, Beedham RJ, Bennett AM, Perkins SD, Miller J, Baillie LW. Presentation of protective antigen to the mouse immune system: immune sequelae. J. Appl. Microbiol.87(2), 315–317 (1999).
   PubMed Web of Science ®Google Scholar
• Williamson ED, Bennett AM, Perkins SD, Beedham RJ, Miller J, Baillie LW. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine20(23–24), 2933–2941 (2002).
   PubMed Web of Science ®Google Scholar
• Galloway D, Liner A, Legutki J, Mateczun A, Barnewall R, Estep J. Genetic immunization against anthrax. Vaccine22(13–14), 1604–1608 (2004).
   PubMed Web of Science ®Google Scholar
• Cui Z, Sloat BR. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid. Int. J. Pharm.317(2), 187–191 (2006).
   PubMedGoogle Scholar
• Mellquist-Riemenschneider JL, Garrison AR, Geisbert JB et al. Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for ebola virus in guinea pigs. Virus Res.92(2), 187–193 (2003).
   PubMed Web of Science ®Google Scholar